Eli Lilly is expected to report Q3 2026 revenue of $22.58 billion and an EPS of $5.38, while the current stock price of $1,273.46 remains below the $1,343.50 analyst consensus price target.
Investors are intensely focused on the commercial launch trajectory of Foundayo, Lilly's first oral GLP-1 weight-loss pill, which represents a critical expansion of its dominant cardiometabolic portfolio.
The company has maintained a seven-quarter streak of earnings beats, driven by the massive demand supercycle for the tirzepatide franchise comprising Mounjaro and Zepbound.
Expectations are high after management recently raised full-year guidance to $85–$87 billion, signaling confidence in manufacturing capacity and continued international market expansion.